Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 854-862

  Asselin, Barbara L ^a   Devidas, Meenakshi ^c   Chen, Lu ^d   Franco, Vivian I ^f   Pullen, Jeanette ^g   Borowitz, Michael J ^h   Hutchison, Robert E ^b   Ravindranath, Yaddanapudi ^f   Armenian, Saro H ^e   Camitta, Bruce M ⁱ   Lipshultz, Steven E ^f  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^g UNIVERSITY OF MISSISSIPPI   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RAZOXANE; VINCRISTINE; ANTINEOPLASTIC AGENT; CARDIOTONIC AGENT; TROPONIN T;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; GROUPS BY AGE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HODGKIN DISEASE; HUMAN; INFECTION; LYMPHOBLASTIC NON HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SECOND CANCER; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T CELL LEUKEMIA; TREATMENT DURATION; TREATMENT INDICATION; BLOOD; CARDIOMYOPATHIES; CHEMICALLY INDUCED; CLINICAL TRIAL; MULTICENTER STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CARDIOTOXICITY; CHILD; DEXRAZOXANE; DOXORUBICIN; FEMALE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME; TROPONIN T;

EID: 84962523680     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.8851     Document Type: Article

References (51)

1. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
2. Schrappe M, Reiter A, Ludwig WD, et al; German-Austrian-Swiss ALL-BFM Study Group: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 95:3310-3322, 2000
3. Goldberg JM, Silverman LB, Levy DE, et al: Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21:3616-3622, 2003
4. Seibel NL, Steinherz PG, Sather HN, et al: Early postinduction intensification therapy improves survival for children and adolescentswith high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111:2548-2555, 2008
5. Oeffinger KC, Mertens AC, Sklar CA, et al: Childhood Cancer Survivor Study: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582, 2006
6. Armstrong GT, Liu Q, Yasui Y, et al: Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 27:2328-2338, 2009
7. Reulen RC, Winter DL, Frobisher C, et al: British Childhood Cancer Survivor Study Steering Group: Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304:172-179, 2010
8. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
9. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
10. Lipshultz SE, Lipsitz SR, Sallan SE, et al: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629-2636, 2005
11. Krischer JP, Epstein S, Cuthbertson DD, et al: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol 15:1544-1552, 1997
12. Nysom K, Colan SD, Lipshultz SE: Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog Pediatr Cardiol 8:121-138, 1998
13. Lipshultz SE, Alvarez JA, Scully RE: Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525-533, 2008
14. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
15. Hudson MM, Ness KK, Gurney JG, et al: Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 309:2371-2381, 2013
16. Myers C: The role of iron in doxorubicininduced cardiomyopathy. Semin Oncol 25:10-14, 1998(suppl 10)
17. Muindi JRF, Sinha BK, Gianni L, et al: Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett 172:226-230, 1984
18. Olson RD, Mushlin PS: Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 4:3076-3086, 1990
19. Hasinoff BB, Hellmann K, Herman EH, et al: Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28, 1998
20. Herman E, Ardalan B, Bier C, et al: Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat Rep 63:89-92, 1979
21. Lebrecht D, Geist A, Ketelsen UP, et al: Dexrazoxane prevents doxorubicin-induced longterm cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151:771-778, 2007
22. Agen C, Bernardini N, Danesi R, et al: Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemother Pharmacol 30:95-99, 1992
23. Speyer JL, Green MD, Kramer E, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745-752, 1988
24. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicincontaining therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
25. Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 25:43-47, 1998(suppl 10)
26. Asselin BL, Devidas M, Wang C, et al: Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: A randomized study by the Children's Oncology Group (POG 9404). Blood 118:874-883, 2011
27. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
28. Colan SD, Parness IA, Spevak PJ, et al: Developmental modulation of myocardial mechanics: Age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 19:619-629, 1992
29. Sluysmans T, Colan SD: Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol (1985) 99:445-457, 2005
30. Venturini M, Michelotti A, Del Mastro L, et al: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996
31. Wexler LH, Weaver-McClure L, Steinberg SM, et al: Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol 14:901-910, 1996
32. Holcenberg JS, Tutsch KD, Earhart RH, et al: Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 70:703-709, 1986
33. Schiavetti A, Castello MA, Versacci P, et al: Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: Preliminary results. Pediatr Hematol Oncol 14:213-222, 1997
34. Bu Lock FA, Gabriel HM, Oakhill A, et al: Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 70:185-188, 1993
35. Schuler D, Horváth E, Koós R, et al: Safety of dexrazoxane in children with all undergoing anthracycline therapy: Preliminary results of a prospective pilot study. Pediatr Hematol Oncol 14:93-94, 1997
36. Van Dalen EC, Caron HN, Dickinson HO, et al: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 6:CD003917, 2011
37. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153, 2004
38. Lipshultz SE, Miller TL, Scully RE, et al: Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes. J Clin Oncol 30:1042-1049, 2012
39. Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007
40. Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961, 2010
41. Hijiya N, Hudson MM, Lensing S, et al: Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 297:1207-1215, 2007
42. Smith MA, Rubinstein L, Anderson JR, et al: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17:569-577, 1999
43. Schrappe M, Nachman J, Hunger S, et al: Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000). Leukemia 24:253-254, 2010
44. Pui CH, Relling MV: Topoisomerase II inhibitorrelated acute myeloid leukemia. Br J Haematol 109:13-23, 2000
45. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25:493-500, 2007
46. Barry EV, Vrooman LM, Dahlberg SE, et al: Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 26:1106-1111, 2008
47. Vrooman LM, Neuberg DS, Stevenson KE, et al: The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 47:1373-1379, 2011
48. Seif AE, Walker DM, Li Y, et al: Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer 62:704-709, 2015
49. Relling MV, Rubnitz JE, Rivera GK, et al: High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354:34-39, 1999
50. Stanulla M, Schaeffeler E, Möricke A, et al: Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood 114:1314-1318, 2009
51. Lipshultz SE, Easley KA, Orav EJ, et al: Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: The prospective P (2) C (2) HIV study. Circulation 104:310-316, 2001